Results 61 to 70 of about 5,464,336 (251)

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Tumor location as a risk factor for severe immune-related adverse events

Journal for ImmunoTherapy of Cancer
Immune-related adverse events (irAEs) can cause severe morbidity and mortality, and they impair treatment with immune checkpoint inhibitors (ICI). Risk factors for irAEs are not well understood.We observed cases of patients having tumor deposits in their
Mike Wang, Michael Dougan, Daniel Leonard, Leyre Zubiri, Ryan J Sullivan, Kerry L Reynolds, Donald P Lawrence, Kamil Slowikowski, Alexandra-Chloe Villani, Steven M Blum, Ben Ouyang, Kelley A Grealish, Nora K Hathaway, Gabriel Molina, Nishi Shah, Mari Mino Kendusen   +15 more
doaj   +1 more source

Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: A retrospective cohort study.

PLoS ONE, 2022
Patients with versus without atopic dermatitis may have a greater risk of cardiovascular events, and the risk increases with severity of atopic dermatitis.
Monique M Hedderson, Maryam M Asgari, Fei Xu, Charles P Quesenberry, Sneha Sridhar, Jamie Geier, Adina R Lemeshow   +6 more
doaj   +1 more source

Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy. [PDF]

, 2014
Few data describe antiretroviral treatment (ART)-related adverse events when treatment is initiated at CD4 cell counts more than 350 cells/μl.
Chadwick, D, Gompels, Mark, Leen, Clifford, Fisher, Martin, Walsh, J, Hill, T, Hill, Teresa, Chadwick, David, Jose, Sophie, Fidler, S, Sabin, Caroline, UK CHIC Steering Committee, Walsh, John, Nelson, M, Sabin, C, Hay, Phillip, Johnson, M, Fidler, Sarah, Post, Frank, Gilson, Richard, Fisher, M, ?, ?, Jose, S, Johnson, Margaret, Quinn, Killian, Post, F, Gilson, R, Quinn, K, Hay, P, Leen, C, Gompels, M, Nelson, Mark   +31 more
core   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

Prinum non nocere: thoughts on the need to develop an 'adverse events' register for complementary and alternative therapies [PDF]

, 2002
Building a body of knowledge to support the eff|cacy and practice of complementary and alternative therapies is an imperative that should be fully embraced by all those involved.
Biley, Francis
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases

Therapeutic Advances in Gastroenterology
Background: Notably, 5-aminosalicylates (5-ASA) are vital in treating inflammatory bowel diseases (IBD). The adverse events of 5-ASA rarely occur but they could be fatal.
Jihye Park, I. Seul Park, Ji Hyung Kim, Jung Hyun Ji, Soo Jung Park, Jae Jun Park, Tae Il Kim, Seung Won Kim, Jae Hee Cheon   +8 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source